Core Viewpoint - The article discusses the performance and holdings of the ICBC Frontier Medical Stock C fund, highlighting its recent growth and ranking among similar funds [1]. Fund Performance - The latest net value of ICBC Frontier Medical Stock C is 2.9850 yuan, reflecting a growth of 3.36% [1]. - The fund's return over the past month is 5.06%, ranking 72 out of 1022 similar funds [1]. - Over the last three months, the return is 10.06%, with a ranking of 63 out of 1009 [1]. - Year-to-date, the fund has achieved a return of 12.46%, ranking 107 out of 999 [1]. Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05% of the fund, with the following key positions: - Heng Rui Medicine: 10.11% - Kelun Pharmaceutical: 8.01% - WuXi AppTec: 7.72% - BeiGene: 6.85% - Xinlitai: 4.90% - Zai Lab: 4.77% - Yuyue Medical: 4.60% - New Horizon: 4.36% - East China Pharmaceutical: 4.20% - Haizhi Pharmaceutical: 3.53% [1]. Fund Background - ICBC Frontier Medical Stock C was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan [1]. - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2].

Core Viewpoint - Zai Jing Pharmaceutical's new drug application for JAK inhibitor, Jika Xitini, has been approved for treating myelofibrosis and related conditions, marking a significant milestone for the company and the domestic pharmaceutical industry [1][2]. Group 1: Drug Approval and Indications - The approved indication for Jika Xitini is for adult patients with intermediate or high-risk primary myelofibrosis (PMF), secondary myelofibrosis due to polycythemia vera (PPV-MF), and secondary myelofibrosis due to essential thrombocythemia (PET-MF), specifically for treating disease-related splenomegaly or symptoms [1]. - Jika Xitini is the first domestically developed JAK inhibitor approved for treating myelofibrosis in China [1]. Group 2: Clinical Trial Results - The approval is based on a Phase III clinical trial showing that 72.3% of patients treated with Jika Xitini had a spleen volume reduction of ≥35% after 24 weeks [2]. - Other clinical endpoints, including clinical improvement, anemia response, hemoglobin improvement, and disease symptom scores, also demonstrated significant benefits [2]. - Phase IIB and II clinical trials for patients intolerant to hydroxyurea and those with refractory or relapsed myelofibrosis showed spleen volume reduction rates of 43.2% and 32.4%, respectively, after 24 weeks [2]. Group 3: Guidelines and Future Research - Jika Xitini has been included in the 2024 CSCO guidelines as a first-line treatment recommendation for myelofibrosis-related anemia and is the preferred option [3]. - The NDA application for Jika Xitini for treating severe alopecia areata has been accepted by the National Medical Products Administration [3]. - Ongoing clinical studies are being conducted for other immune-inflammatory diseases, including moderate to severe atopic dermatitis and ankylosing spondylitis [3].

Core Viewpoint - Suzhou Zejing Biopharmaceutical Co., Ltd. announced that its self-developed drug, JAK inhibitor Jikaxitinib (brand name: Zepuping), has received approval for marketing in China, targeting specific types of myelofibrosis in adult patients [1][2][3] Drug Basic Information - Drug Name: Jikaxitinib - Dosage Form: Tablet - Specification: 50mg - Marketing Authorization Holder: Suzhou Zejing Biopharmaceutical Co., Ltd. - Indications: For adult patients with intermediate or high-risk primary myelofibrosis (PMF), secondary myelofibrosis due to polycythemia vera (PPV-MF), and secondary myelofibrosis due to primary thrombocythemia (PET-MF), treating disease-related splenomegaly or symptoms [1][2] Drug Mechanism and Clinical Trials - Jikaxitinib is a novel JAK inhibitor that works by inhibiting the activity of JAK1, JAK2, JAK3, and TYK2, blocking the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [2] - The approval is based on a Phase III clinical trial showing that 72.3% of patients had a ≥35% reduction in spleen volume after 24 weeks of treatment [3] - Other clinical trials indicated good safety and tolerability profiles for Jikaxitinib in the target patient population [3] Market Potential and Competitive Landscape - The annual incidence of myelofibrosis in China is approximately 60,000 new patients, with a total patient population exceeding 200,000 [5] - The market size for myelofibrosis drugs in China was 1.73 billion yuan in 2020, projected to grow to 2.93 billion yuan by 2025 and 3.30 billion yuan by 2030 [5] - Currently, the only approved targeted drug for treating intermediate and high-risk myelofibrosis in China is the imported drug Ruxolitinib, which had a global sales figure of approximately 4.9 billion USD in 2024 [5] Regulatory and Clinical Guidelines - Jikaxitinib has been included in the 2024 CSCO guidelines as a first-line treatment for myelofibrosis-related anemia and is recommended for second-line and advanced treatment [4] - The drug is also undergoing clinical trials for other immune-inflammatory diseases, including atopic dermatitis and ankylosing spondylitis [4]

证券代码：688266 证券简称：泽璟制药 公告编号：2025-024 苏州泽璟生物制药股份有限公司 关于自愿披露盐酸吉卡昔替尼片获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 由于医药行业的特点，药品上市后的具体销售情况受政策环境、市场需求及 竞争状况等多种因素的影响，存在一定的不确定性，公司将及时根据后续进展履 行信息披露义务。敬请广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 一、药品基本情况 | 药品名称 | 盐酸吉卡昔替尼片 | | --- | --- | | 商品名 | 泽普平 | | 剂型 | 片剂 | | 规格 | 50mg | | 上市许可持有人 | 苏州泽璟生物制药股份有限公司 | | 生产企业 | 苏州泽璟生物制药股份有限公司 | | 适应症 | 本品适用于中危或高危原发性骨髓纤维化（PMF）、真 性红细胞增多症继发性骨髓纤维化（PPV-MF）和原发 性血小板增多症继发性骨纤维化（PET-MF）的成人患 | | | 者，治疗疾病相关脾肿大或疾病相关症状。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed drug, JAK inhibitor, which is indicated for adult patients with intermediate or high-risk primary myelofibrosis [1] Group 1: Drug Approval and Indications - The drug, Hydrochloride Jikaxitinib Tablets (Zepuping), is approved for use in adult patients with intermediate or high-risk primary myelofibrosis and other related diseases [1] - This drug is classified as a Class 1 new drug and works by inhibiting the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [1] Group 2: Clinical Trial Results - According to Phase III clinical trials, 72.3% of participants showed a reduction in spleen volume of ≥35% from baseline after 24 weeks of treatment, indicating significant therapeutic benefits [1] Group 3: Clinical Guidelines - Hydrochloride Jikaxitinib Tablets have been included in the "2024 Guidelines for the Diagnosis and Treatment of Malignant Hematological Diseases" by the Chinese Society of Clinical Oncology (CSCO) as a Class I recommendation for first-line stratified treatment of myelofibrosis [1]

Core Viewpoint - The Chinese innovative pharmaceutical industry is transitioning from imitation to original innovation, with significant growth in outbound transactions and a promising future for internationalization [4] Group 1: Market Performance - As of May 29, 2025, the Sci-Tech Innovation Board 100 Index (000698) rose by 1.63%, with notable increases in constituent stocks such as Borui Pharmaceutical (688166) up 9.66% and Zhixiang Jintai (688443) up 6.57% [3] - The Sci-Tech 100 Index ETF (588030) increased by 1.60%, with a latest price of 0.95 yuan and a turnover rate of 1.16%, totaling 71.56 million yuan in transactions [3] - Over the past year, the average daily transaction volume of the Sci-Tech 100 Index ETF reached 424 million yuan, ranking first among comparable funds [3] Group 2: Fund Growth and Performance - The Sci-Tech 100 Index ETF saw a significant increase in scale, growing by 94.45 million yuan over the past two weeks, ranking second among comparable funds [4] - In the past week, the ETF's shares increased by 99 million, also ranking first among comparable funds [5] - The ETF has experienced a net inflow of 71.08 million yuan over the last five trading days, indicating strong investor interest [5] Group 3: Financial Metrics - As of May 28, 2025, the Sci-Tech 100 Index ETF's net value increased by 19.94% over the past year, with a maximum monthly return of 27.67% since inception [5] - The ETF's management fee is 0.15% and the custody fee is 0.05%, making it the lowest among comparable funds [5] - The tracking error for the ETF over the past six months is 0.016%, indicating high tracking precision compared to similar funds [5] Group 4: Industry Insights - From the beginning of 2025 to the present, the total outbound transaction amount for innovative drugs has reached 45.5 billion USD, with upfront payments totaling 2.2 billion USD, suggesting a record year ahead [4] - Most domestic innovative drugs currently in the U.S. are in clinical stages, with significant potential for future growth as they progress towards commercialization [4]

Core Viewpoint - The Chinese innovative pharmaceutical sector is gaining international recognition, highlighted by significant deals and promising clinical data, leading to increased interest in related ETFs [1][3][4]. Group 1: Market Performance - The innovative drug ETF (517110) has rebounded nearly 15% since early April, reflecting strong performance in the pharmaceutical sector [1]. - The biopharmaceutical ETF and vaccine ETF also showed positive movements, with respective increases of 1.17% and 0.89% [2]. Group 2: ASCO Conference Insights - At the 2025 ASCO conference, over 70 research outcomes from Chinese pharmaceutical companies were presented, showcasing advancements in ADC and bispecific antibody technologies [3]. - Notable performances include Zai Lab's ZG005 and Huahai Pharmaceutical's HB0025, which exceeded expectations in early clinical trials for cervical and endometrial cancers, respectively [3]. Group 3: Business Development Trends - Recent business development (BD) activities in the innovative drug sector have seen record-breaking upfront payments, such as the $12.5 billion upfront payment from Pfizer for a PD-1/VEGF bispecific antibody from 3SBio [4][7]. - The increase in upfront payments and total deal values indicates growing international recognition of Chinese innovative drugs [7]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from ongoing BD transactions, advancements in artificial intelligence across the pharmaceutical value chain, and the implementation of new healthcare policies [7]. - The overall sentiment and valuation in the pharmaceutical sector may improve due to domestic policy optimizations and a recovery in medical equipment procurement [7].

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].

Group 1 - The core point of the article highlights the performance and holdings of the Industrial Bank's Frontier Medical Stock A fund, which has a recent net value of 2.9540 yuan, reflecting a decline of 1.86% [1] - The fund's one-month return is 4.79%, ranking 62 out of 864 in its category; the three-month return is 9.08%, ranking 51 out of 853; and the year-to-date return is 12.28%, ranking 93 out of 850 [1] - The top ten holdings of the fund account for a total of 59.05%, with significant positions in companies such as Heng Rui Pharmaceutical (10.11%), Kelun Pharmaceutical (8.01%), and WuXi AppTec (7.72%) [1] Group 2 - The Industrial Bank's Frontier Medical Stock A fund was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - Zhao Bei serves as the fund manager and has extensive experience in the healthcare sector, having held various positions since joining Industrial Bank in 2010 [2]

Core Viewpoint - The article discusses the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of the ICBC Medical Healthcare Stock Fund is 2.5580 yuan, reflecting a decrease of 1.16% - The fund's return over the past month is 3.52%, ranking 172 out of 940 in its category - Over the last six months, the return is 9.79%, with a ranking of 202 out of 914 - Year-to-date, the return stands at 12.24%, ranking 98 out of 926 [1]. Fund Holdings - The top ten holdings of the ICBC Medical Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuwell Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Medical Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [1][2].